Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
An oral pan-ERR agonist studied in exercise-mimetic research (not a peptide), with JPET 2026 preclinical data, a linked monograph, and a per-LOT COA.
Size: 10 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (oral) | 1 mg per day | Starting dose |
| Titration | 1–2 mg per day | Increase if needed |
| Upper reference in this schedule | up to 2–3 mg per day (may be split into 2 doses) | Maximum in this schedule |
Share your experience
No reviews yet. Tell others what you think of this product.
SLU-PP-915 is studied as part of the "exercise-mimetic" research field — work that tries to pharmacologically reproduce part of the molecular effect of physical exercise on muscle. It is a synthetic small molecule, a pan-agonist of the estrogen-related receptors ERRα/β/γ, developed at Saint Louis University in the Thomas Burris programme. It is not a peptide. And, despite a shared origin, it is not simply a "version of SLU-PP-332": 915 is built on a thiophene scaffold with a boronic acid moiety, whereas 332 is an acylhydrazone. The JPET authors explicitly call 915 a chemically distinct pan-ERR agonist.
The reason 915 exists at all is pharmacokinetic. SLU-PP-332 is metabolically unstable, and in studies it was given by injection. Hampton et al. (Eur J Med Chem, 2023) showed that replacing the phenol or aniline group with a boronic acid preserves activity at ERR (EC₅₀ ≈ 414 / 435 / 378 nM for ERRα/β/γ) while raising stability in human and mouse liver microsomes (T½ ≥ 60 min). This gave the series its first orally bioavailable member.
In preclinical work by Billon et al. (J Pharmacol Exp Ther, 2026) oral SLU-PP-915 in mice increased aerobic capacity and induced the Ddit4 gene to a level comparable to treadmill running, and in combination with training it further enhanced expression of mitochondrial genes. No human studies exist: the entire evidence base is limited to cell models and mice, and no conclusions about an effect in humans can be drawn from it.
A separate line of work (Möller et al., Rapid Commun Mass Spectrom, 2026) described seven phase I metabolites and analytical targets for doping control: the compound is being studied as a potential object of abuse in sport, although it is not currently on the WADA Prohibited List.
A related compound in the same category is SLU-PP-332; the rest of the category is ERR agonists.
